RxDoctor Payments Data

Jenny Oh, MD

Rheumatology · Tarzana, CANPI 1386657856

Payments from drug & device makers

$26,115in general payments, 2019–2025

Across 1,389 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Amgen$5K
  • Johnson & Johnson$4K
  • Novartis$3K
  • GSK$1K
  • AstraZeneca$1K
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$1,6406%
  • Speaking & faculty fees$1,1004%
  • Grants$2401%
  • Travel & lodging$260%
  • Food & beverage$23,01388%
  • Education$960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,115 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$1,723,011
Medicare patients
618
Services billed
99,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$300,577
Enbrel SureclickEtanercept19$135,139
Simponi AriaGolimumab18$127,554
Humira(Cf) PenAdalimumab15$98,751
EnbrelEtanercept11$82,536
Xeljanz XrTofacitinib Citrate11$60,989
OrenciaAbatacept/Maltose12$59,180
Evenity (2 Syringes)Romosozumab-Aqqg18$46,502
Teriparatide21$27,827
ProliaDenosumab11$18,891
ActemraTocilizumab12$17,820
Leflunomide82$5,681
MethotrexateMethotrexate Sodium179$5,344
Mycophenolate Mofetil18$4,760
Hydroxychloroquine Sulfate80$3,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi Aria$3,655$428,13130 claims
AmgenEnbrel, Evenity (2 Syringes), Prolia$4,727$147,92940 claims
E.r. Squibb & Sons, L.L.C.Orencia$464$59,18012 claims
Alvogen IncTeriparatide$30$27,82721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.

Other rheumatology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →